Kanker prostat iyanaritu kanker kaminang macahoro maduwa ri urane ri yamaneng linoe, sibawa kira-kira 1.276 juta kasus baru iya riraporkang ri taung 2018, nawakkeleki 7.1% pole yamaneng kasus kanker ri urane.
Angka amatengeng untu' kanker prostat to matanre, sibawa kira-kira 37.005 amatengeng ri yamaneng lino ri taung 2018.
Namuni, kadarana amatengeng e maega ladde pole ri onrongnge, sibawa Afrika Barat punnai resiko kaminang matanre kalima untu' amatengeng kanker prostat ri linoe, nenniya Nigeria punnai populasi nenniya ekonomi kaminang maraja ri onrongnge.
Ri Nigeria, kanker prostat iyanaritu kanker kaminang macahoro nenniya kaminang masero untu' urane, sibawa kira kira 32,8 kasus nenniya 16,3 amateng ri tungke 100.000 urane.
Iyyae lebbi pole wekkaduwa angke amatengeng ri Amerika Utara.
Attangngaana lasae, pakkulleng iya maponco' untu' apparessang nenniya attangngaana, nenniya makurangna dokumentasi nenniya laporang kasus natambai lao ri tingka amatengeng matanre ri Nigeria.
Ri Amerika Serikat, kanker prostat iyanaritu saba' maduwa kaminang macahoro amateng pole kanker ri urane, sibawa kira kira 40.0000 urane matena pole lasa e tungke taung.
Secara maloppo, kanker prostat iyanaritu lasa iya mabbuno, utamana ri daera sibawa akses iya ribatasi lao ri perawatan medis nenniya sumber daya skrining.
Nakata S, Takahashi H, Ohtake N, Takei T, Yamanaka H: Trends and characteristics in prostate cancer mortality in Japan. Int J Urol. 2000, 7 (7): 254-7.
Pishgar F, Ebrahimi H, Saeedi Moghaddam S, Fitzmaurice C, Amini E: Global, Regional and National Burden of Prostate Cancer, 1990 to 2015: Results from the Global Burden of Disease Study 2015. J Urol. 2018, 199 (5): 1224-1232.
Cai Q, Chen Y, Zhang D, Pan J, Xie Z, Xu C, Li S, Zhang X, Gao Y, Hou J, Guo X, Zhou X, Zhang B, Ma F, Zhang W, Lin G, Xin Z, Niu Y, Wang Y: Estimates of over-time trends in incidence and mortality of prostate cancer from 1990 to 2030. Transl Androl Urol. 2020, 9 (2): 196-209.
Feletto E, Bang A, Cole-Clark D, Chalasani V, Rasiah K, Smith DP: An examination of prostate cancer trends in Australia, England, Canada and USA: Is the Australian death rate too high? World J Urol. 2015, 33 (11): 1677-87.
Taksler GB, Keating NL, Cutler DM: Explaining racial differences in prostate cancer mortality. Cancer. 2012, 118 (17): 4280-9.
['Atassalang: medis']
["Iyyae situs web e ripassedia untu' akkatta-akkatta pendidikan nenniya informasi bawang na de'na mabbere saran medis iyarega layanan profesional."]
["Rilaleng iyyae, jaringang saraf iya makkewassele bali lao ri pakkutanae, de'na coco narekko engka assisompungenna sibawa angke. contona, egana tau iya riruntue sibawa lasa mattentu."]
["Tuli sappai pangajana doktere'mu iyarega pajjama kesehatang laingnge iyya engkae kualifikasi'e ri tujunna keadaang medis'e. Aja' naengka muwallupai pangajana doktere' iyarega matengnge ri laleng sappa'na nasaba engka aga pura mubaca ri situs web'e. Narekko muwasengngi engka passaleng medis iya parellu'e ripassappa, mobbii 911 iyarega lao ri ruang darurat kaminang macawe'e masitta'. De gaga assisompungeng doktere-pasien iyya ripancaji pole situs web'e iyarega akkegunanna. BioMedLib iyarega pajjamana, iyarega muwi niga pattarima lao ri situs web'e, de nawerengngi aga-aga, manessa iyarega tersirat, ri tujunna kareba iyya riyabbere'e iyarega akkegunanna."]
['Disclaimer: hak cipta']
["Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the DMCA) mabbere daya tarik lao ri punnana hak cipta iya mateppe'e majeppuu agaaga iya engkae ri Internet naruntu'i hakna ri yawa hukung hak cipta AS. "]
["Narekko mateppe'ko sibawa makessing majeppuu agaaga lise'na iyarega agaaga iya engkae ri laleng situs web iyarega jasae naruntu'i hak cipta'mu, iko (iyarega agenna) wedding kiringki pappaseng iyya naeloriwi lise' iyarega agaaga ripassu, iyarega akses lao ri iyyae ritongkoi."]
["DMCA parellu i nawereng pappaseng mu ri palanggarang hak cipta nawereng i pappaseng iyyae: (1) pappaseng pole ri jama-jamang hak cipta iyyae mancaji pakkitanna palanggarang iya nawereng i; (2) pappaseng pole ri konten iya nawereng i nenniya pappaseng iya genne'e untu' nawereng i onrong konten e; (3) pappaseng assisumpungemmu, matame' alamat, nomoro' telepon, nenniya alamat emailmu; (4) pappaseng pole ri iko makkedae iko mateppe'i majeppu konten iya engkae rilalenna pappaseng iyya mu nawereng i de'na ripalaloi pole ri punnana hak cipta, iyarega agen na, iyarega pole ri hukum e; "]
["(5) seddi pappaseng pole ri iko, ritanrai ri yawa pahukkungeng sabbi bellé, makkeda kareba ri laleng pappasengnge coco'i sibawa iko mappunnaiwi otoritas untu' napake hak cipta iya rituntut pura rikalang;"]
["nenniya (6) tanrang lima fisik iyarega elektronik pole punnana hak cipta iyarega tau iya ripalalo e untu' majjama ri laleng asenna punnana hak cipta e. "]
Prostate cancer is the second most common cancer in men worldwide, with an estimated 1.276 million new cases reported in 2018, representing 7.1% of all cancer cases in men.
The mortality rate for prostate cancer is also high, with an estimated 37,005 deaths worldwide in 2018.
However, the mortality rate varies greatly by region, with Western Africa having the fifth-highest risk for prostate cancer mortality in the world, and Nigeria having the largest population and economy in this region.
In Nigeria, prostate cancer is both the most common and most deadly cancer for men, with an estimated 32.8 cases and 16.3 deaths per 100,000 men.
This is more than double the death rate in North America.
Late detection of the disease, limited resources for screening and detection, and decreased documentation and reporting of cases contribute to the high mortality rate in Nigeria.
In the United States, prostate cancer is the second most common cause of cancer death in men, with approximately 40,0000 men dying from the disease each year.
The prostate cancer death rate has been slowly decreasing since the early 1990s, but it remains a significant health concern.
Overall, prostate cancer is a deadly disease, particularly in regions with limited access to medical care and screening resources.
However, early detection and treatment can significantly improve outcomes and reduce mortality rates.
Disclaimer: medical
This web site is provided for educational and informational purposes only and does not constitute providing medical advice or professional services.
The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician.
Please note the neural net that generates answers to the questions, is specially inaccurate when it comes to numeric content. For example, the number of people diagnosed with a specific disease.
Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you think you may have a medical emergency, call 911 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. Neither BioMedLib nor its employees, nor any contributor to this web site, makes any representations, express or implied, with respect to the information provided herein or to its use.
Disclaimer: copyright
The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the “DMCA”) provides recourse for copyright owners who believe that material appearing on the Internet infringes their rights under U.S. copyright law. If you believe in good faith that any content or material made available in connection with our website or services infringes your copyright, you (or your agent) may send us a notice requesting that the content or material be removed, or access to it blocked. Notices must be sent in writing by email (see 'Contact' section for email address) . The DMCA requires that your notice of alleged copyright infringement include the following information: (1) description of the copyrighted work that is the subject of claimed infringement; (2) description of the alleged infringing content and information sufficient to permit us to locate the content; (3) contact information for you, including your address, telephone number and email address; (4) a statement by you that you have a good faith belief that the content in the manner complained of is not authorized by the copyright owner, or its agent, or by the operation of any law; (5) a statement by you, signed under penalty of perjury, that the information in the notification is accurate and that you have the authority to enforce the copyrights that are claimed to be infringed; and (6) a physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner’s behalf. Failure to include all of the above information may result in the delay of the processing of your complaint.
